ViroGates A/S
CSE:VIRO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.4
22
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
ViroGates A/S
Total Liabilities & Equity
ViroGates A/S
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
ViroGates A/S
CSE:VIRO
|
Total Liabilities & Equity
kr14.1m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
GN Store Nord A/S
CSE:GN
|
Total Liabilities & Equity
kr29.6B
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Ambu A/S
CSE:AMBU B
|
Total Liabilities & Equity
kr7.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Demant A/S
CSE:DEMANT
|
Total Liabilities & Equity
kr32.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
|
ViroGates A/S
Glance View
ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
See Also
What is ViroGates A/S's Total Liabilities & Equity?
Total Liabilities & Equity
14.1m
DKK
Based on the financial report for Sep 30, 2024, ViroGates A/S's Total Liabilities & Equity amounts to 14.1m DKK.
What is ViroGates A/S's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-23%
Over the last year, the Total Liabilities & Equity growth was -3%. The average annual Total Liabilities & Equity growth rates for ViroGates A/S have been -15% over the past three years , -23% over the past five years .
You don't have any saved screeners yet
